FSTL1 and cirrhosis of liver: Our data suggest that FSTL1 promotes early macrophage recruitment to facilitate subsequent effective macrophage accumulation during stem cell therapy, and could potentially serve as a predictive biomarker of the response to stem cell therapy in patients with liver cirrhosis.